149 related articles for article (PubMed ID: 26321323)
1. Empirical treatment in patients with acute obstructive pyelonephritis.
Pasiechnikov S; Buchok O; Sheremeta R; Banyra O
Infect Disord Drug Targets; 2015; 15(3):163-70. PubMed ID: 26321323
[TBL] [Abstract][Full Text] [Related]
2. Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.
Wagenlehner FM; Sobel JD; Newell P; Armstrong J; Huang X; Stone GG; Yates K; Gasink LB
Clin Infect Dis; 2016 Sep; 63(6):754-762. PubMed ID: 27313268
[TBL] [Abstract][Full Text] [Related]
3. Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high.
Jeon JH; Kim K; Han WD; Song SH; Park KU; Rhee JE; Song KH; Park WB; Kim ES; Park SW; Kim NJ; Oh MD; Kim HB
Antimicrob Agents Chemother; 2012 Jun; 56(6):3043-6. PubMed ID: 22391544
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact.
Shin J; Kim J; Wie SH; Cho YK; Lim SK; Shin SY; Yeom JS; Lee JS; Kweon KT; Lee H; Cheong HJ; Park SH; Park DW; Ryu SY; Chung MH; Yoo S; Pai H
Microb Drug Resist; 2012 Apr; 18(2):169-75. PubMed ID: 22400491
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study.
Vazquez JA; González Patzán LD; Stricklin D; Duttaroy DD; Kreidly Z; Lipka J; Sable C
Curr Med Res Opin; 2012 Dec; 28(12):1921-31. PubMed ID: 23145859
[TBL] [Abstract][Full Text] [Related]
6. Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis.
Lee SS; Kim Y; Chung DR
J Infect; 2011 Feb; 62(2):159-64. PubMed ID: 21055417
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections.
Levine DP; McNeil P; Lerner SA
Am J Med; 1989 Nov; 87(5A):160S-163S. PubMed ID: 2686416
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial.
Talan DA; Stamm WE; Hooton TM; Moran GJ; Burke T; Iravani A; Reuning-Scherer J; Church DA
JAMA; 2000 Mar 22-29; 283(12):1583-90. PubMed ID: 10735395
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic therapy for acute uncomplicated pyelonephritis in women. Take resistance into account.
Prescrire Int; 2014 Dec; 23(155):296-300. PubMed ID: 25629148
[TBL] [Abstract][Full Text] [Related]
10. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis.
Talan DA; Klimberg IW; Nicolle LE; Song J; Kowalsky SF; Church DA
J Urol; 2004 Feb; 171(2 Pt 1):734-9. PubMed ID: 14713799
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of intravenous ciprofloxacin in the treatment of serious infections. A comparison with ceftazidime.
Quintero-Perez NP; Andrade-Villaneuva JF; Leon-Garnica G; Bertin-Montano M; Rodriguez-Chagollan JJ; Rodriguez-Noriega E
Am J Med; 1989 Nov; 87(5A):198S-201S. PubMed ID: 2686424
[TBL] [Abstract][Full Text] [Related]
12. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
13. Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.
Wagenlehner F; Nowicki M; Bentley C; Lückermann M; Wohlert S; Fischer C; Vente A; Naber K; Dalhoff A
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339395
[TBL] [Abstract][Full Text] [Related]
14. Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding.
Sifuentes-Osornio J; Macías A; Amieva RI; Ramos A; Ruiz-Palacios GM
Am J Med; 1989 Nov; 87(5A):202S-205S. PubMed ID: 2686425
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of ureteroscopy after obstructive pyelonephritis treatment.
Kanno T; Matsuda A; Sakamoto H; Higashi Y; Yamada H
Int J Urol; 2013 Sep; 20(9):917-22. PubMed ID: 23347168
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections.
Gallis HA; Brennan RO; Goodwin SD; Swinney V; Rumbaugh MM; Drew RH
Am J Med; 1989 Nov; 87(5A):176S-180S. PubMed ID: 2686418
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis.
Cox CE; Marbury TC; Pittman WG; Brown GL; Auerbach SM; Fox BC; Yang JY
Clin Ther; 2002 Feb; 24(2):223-36. PubMed ID: 11911553
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with ciprofloxacin- and cefotaxime-resistant Escherichia coli in women with acute pyelonephritis in the emergency department.
Park KH; Oh WS; Kim ES; Park SW; Hur JA; Kim YK; Moon C; Lee JH; Lee CS; Kim BN
Int J Infect Dis; 2014 Jun; 23():8-13. PubMed ID: 24657271
[TBL] [Abstract][Full Text] [Related]
19. A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis.
Fox MT; Melia MT; Same RG; Conley AT; Tamma PD
Am J Med; 2017 Jul; 130(7):842-845. PubMed ID: 28216442
[TBL] [Abstract][Full Text] [Related]
20. A Cohort Study of Risk Factors That Influence Empirical Treatment of Patients with Acute Pyelonephritis.
Bosch-Nicolau P; Falcó V; Viñado B; Andreu A; Len O; Almirante B; Pigrau C
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
